Bigul

INDOCO REMEDIES LTD. - 532612 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company INDOCO REMEDIES LTD. 2 CIN NO. L85190MH1947PLC005913 3 Report filed for FY 2022-2023 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2022-23, FY 2023-24, FY 2024-25 5 Incremental borrowing done in FY (T)(a) 95.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2021-22, FY 2022-23, FY 2023-24 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Ramanathan HariharanDesignation :-Company Secretary and Head Legal Name of the Chief Financial Officer :- Pramod Ghorpade Designation : -Chief Financial Officer Date:...
28-04-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyINDOCO REMEDIES LTD. 2CIN NO.L85190MH1947PLC005913 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 190.04 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Ramanathan Hariharan Designation: Company Secretary and Head Legal EmailId: [email protected] Name of the Chief Financial Officer: Pramod Ghorpade Designation: Chief Financial Officer EmailId: [email protected] Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
28-04-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Notice for transfer of equity shares of the Company to the Investor Education and Protection Fund ('IEPF').
27-04-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Certification Under Regulation 40(9) Read With Regulation 40(10) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended 31St March, 2023

Certificate received from A.Y. Sathe & Co., Practicing Company Secretaries, certifying compliance with Regulation 40(9) read with Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the year ended 31st March, 2023.
27-04-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2023
10-04-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Compliance Certificate For The Year Ended 31-03-2023

Compliance Certificate - Regulation 7 (3) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015
04-04-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M. Panandikar
31-03-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Closure of Trading Window

Intimation regarding Closure of Trading Window
30-03-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Intimation Of Appointment Of Secretarial, Internal And Cost Auditors Of The Company For The Financial Year 2023-24 Pursuant To Regulation 30 Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015

1. Re-appointment of M/s A. Y. Sathe & Co, Practicing Company Secretaries, (FCS 2899, COP: 738) as Secretarial Auditor of the Company for the financial year 2023-24. 2. Re-appointment of M/s B. K. Khare & Co., Chartered Accountants having firm Registration No. 105102W as Internal Auditors of the Company for the financial year 2023-24. 3. Re-Appointment of M/s Joshi Apte and Associates, Cost Accountants, having firm Registration No. 00240 as the Cost Auditors of the Company for the financial year 2023-24.
29-03-2023
Bigul

INDOCO REMEDIES LTD. - 532612 - Announcement Under Regulation 30 (LODR)- Updates (USFDA Inspection At Indoco Remedies Limited'S Plant II (Sterile Facility) And Plant III (OSD Facility) At Goa)

We would like to inform you that the United States Food and Drug Administration (USFDA) has conducted GMP inspection of Plant II (Sterile Facility) and Plant III (OSD Facility) at Goa. The inspection was conducted from 20th February, 2023 to 28th February, 2023. The USFDA has issued Form 483 with four (4) observations, which will be addressed within stipulated time. We believe that this will not have an impact on the supplies and the existing revenues from these Facilities. The Company is committed to maintain compliances across all our facilities with cGMP quality standards at all times. This is for your information and record.
01-03-2023
Next Page
Close

Let's Open Free Demat Account